Topical Imiquimod Treatment for Nodular Basal Cell Carcinomas: An Open-Label Series

Abstract

Imiquimod 5% cream may be another treatment modality for nodular BCC.

Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study

“…In this study, a local recurrence of BCC was not observed clinically within the 3-year follow-up period. The rates of clearance and recurrence in these patients are in accordance with those reported in previous studies that focused on other tumour locations [3,4]. In another study, 5% imiquimod was applied to the eyelids with good results in terms of clearance, but the authors state that the excellent recurrence rate was tentative because of the short-term follow-up time [5].…”

“…Recent studies recommend the expansion of its use as an effective non-surgical treatment of nodular BCC [3].…”

Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids

“…Imiquimod probably stimulates a cell-mediated immunity, which is naturally suppressed by BCC, and can clear the tumor [5,6]. Nevertheless, there are five histopathological types of BCC: nodular, superficial, micronodular, morpheaform, and sclerosing, of which superficial and nodular BCCs are considered nonaggressive forms [7]. Nodular BCC is the most common tumor type in the region of the eyelids (78%) [8].…”

The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions

“…It has been reported to have clinical efficacy in the management of both superficial3 4 and nodular basal cell carcinomas (BCCs) 5 6…”